FRIDAY, Feb. 21, 2025 -- For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2...

Losing and regaining weight repeatedly—a pattern known as yo-yo dieting or body-weight cycling—can significantly increase the risk of kidney...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity,...

FRIDAY, Jan. 14, 2025 -- Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one...

FRIDAY, Feb. 7, 2025 -- Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the field of...

TUESDAY, Feb. 11, 2025 -- Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular...

Highlights: High body weight variability is linked to chronic kidney disease in type 1 diabetes Maintaining stab

Body weight cycling in type 1 diabetes is associated with increased risk of chronic kidney disease. Maintaining stable weight may help prevent renal...

Researchers at Texas A&M University College of Medicine have developed a new therapy that may slow the progression of Alzheimer’s disease by several...